413 related articles for article (PubMed ID: 25381900)
1. Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.
Somasundaram A; Socinski MA; Burns TF
Expert Opin Pharmacother; 2014 Dec; 15(18):2693-708. PubMed ID: 25381900
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase inhibitors to treat non-small-cell lung cancer.
Minuti G; D'Incecco A; Landi L; Cappuzzo F
Expert Opin Pharmacother; 2014 Jun; 15(9):1203-13. PubMed ID: 24745764
[TBL] [Abstract][Full Text] [Related]
3. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
Yamaguchi N; Lucena-Araujo AR; Nakayama S; de Figueiredo-Pontes LL; Gonzalez DA; Yasuda H; Kobayashi S; Costa DB
Lung Cancer; 2014 Jan; 83(1):37-43. PubMed ID: 24199682
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
[TBL] [Abstract][Full Text] [Related]
5. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC.
Zhang YC; Zhou Q; Wu YL
Expert Opin Pharmacother; 2016 Aug; 17(12):1693-701. PubMed ID: 27359268
[TBL] [Abstract][Full Text] [Related]
9. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
Cameron L; Solomon B
Drugs; 2015 Jul; 75(10):1059-70. PubMed ID: 26076736
[TBL] [Abstract][Full Text] [Related]
10. New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.
Cameron L; Solomon B
Curr Treat Options Oncol; 2015 Oct; 16(10):49. PubMed ID: 26318457
[TBL] [Abstract][Full Text] [Related]
11. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
12. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
13. Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
Miyawaki M; Yasuda H; Tani T; Hamamoto J; Arai D; Ishioka K; Ohgino K; Nukaga S; Hirano T; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
Mol Cancer Res; 2017 Jan; 15(1):106-114. PubMed ID: 27707887
[TBL] [Abstract][Full Text] [Related]
14. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of patients with ALK gene rearranged non-small cell lung cancer
after resistance to crizotinib].
Jiang T; Zhou C
Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):69-74. PubMed ID: 25676398
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
Chuang JC; Neal JW; Niu XM; Wakelee HA
Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
[TBL] [Abstract][Full Text] [Related]
17. Management of NSCLC: focus on crizotinib.
Landi L; Cappuzzo F
Expert Opin Pharmacother; 2014 Dec; 15(17):2587-97. PubMed ID: 25301075
[TBL] [Abstract][Full Text] [Related]
18. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
19. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH
Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V
Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]